JP2006507319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006507319A5 JP2006507319A5 JP2004550987A JP2004550987A JP2006507319A5 JP 2006507319 A5 JP2006507319 A5 JP 2006507319A5 JP 2004550987 A JP2004550987 A JP 2004550987A JP 2004550987 A JP2004550987 A JP 2004550987A JP 2006507319 A5 JP2006507319 A5 JP 2006507319A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridylmethyl
- mesothelioma
- phthalazine
- day
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WHOWNXIYXLWMGJ-UHFFFAOYSA-N 1-(pyridin-4-ylmethyl)phthalazine Chemical class N=1N=CC2=CC=CC=C2C=1CC1=CC=NC=C1 WHOWNXIYXLWMGJ-UHFFFAOYSA-N 0.000 claims description 10
- -1 pyridylmethyl phthalazine derivatives Chemical class 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 150000001875 compounds Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 7
- 206010027406 Mesothelioma Diseases 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 241000534944 Thia Species 0.000 claims 2
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 claims 2
- 206010073062 Biphasic mesothelioma Diseases 0.000 claims 1
- 206010035603 Pleural mesothelioma Diseases 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 201000010117 malignant biphasic mesothelioma Diseases 0.000 claims 1
- 208000014699 malignant epithelioid mesothelioma Diseases 0.000 claims 1
- 208000024407 malignant pericardial mesothelioma Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000004266 pericardial mesothelioma Diseases 0.000 claims 1
- 201000002513 peritoneal mesothelioma Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 150000003890 succinate salts Chemical group 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42548302P | 2002-11-12 | 2002-11-12 | |
| PCT/EP2003/012593 WO2004043459A1 (en) | 2002-11-12 | 2003-11-11 | Treatment of mesothelioma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006507319A JP2006507319A (ja) | 2006-03-02 |
| JP2006507319A5 true JP2006507319A5 (enExample) | 2007-01-18 |
Family
ID=32312997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004550987A Pending JP2006507319A (ja) | 2002-11-12 | 2003-11-11 | 中皮腫の処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20060058313A1 (enExample) |
| EP (1) | EP1562591A1 (enExample) |
| JP (1) | JP2006507319A (enExample) |
| AU (1) | AU2003288034A1 (enExample) |
| WO (1) | WO2004043459A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| DE60018225T2 (de) * | 1999-03-01 | 2005-12-29 | Pfizer Products Inc., Groton | Oxamsäuren mit einer Cyanogruppe als Liganden für den Thyroidrezeptor |
| AR025068A1 (es) * | 1999-08-10 | 2002-11-06 | Bayer Corp | Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis |
| US7179912B2 (en) * | 2000-09-01 | 2007-02-20 | Icos Corporation | Materials and methods to potentiate cancer treatment |
-
2003
- 2003-11-11 JP JP2004550987A patent/JP2006507319A/ja active Pending
- 2003-11-11 AU AU2003288034A patent/AU2003288034A1/en not_active Abandoned
- 2003-11-11 WO PCT/EP2003/012593 patent/WO2004043459A1/en not_active Ceased
- 2003-11-11 US US10/534,572 patent/US20060058313A1/en not_active Abandoned
- 2003-11-11 EP EP03779888A patent/EP1562591A1/en not_active Withdrawn
-
2006
- 2006-09-26 US US11/527,269 patent/US20070021432A1/en not_active Abandoned
-
2009
- 2009-04-29 US US12/432,112 patent/US20090239872A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2508110C2 (ru) | КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek | |
| AU2016216636B2 (en) | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity | |
| RU2012147511A (ru) | Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза | |
| US20130045983A1 (en) | Hsp90 inhibitors for therapeutic treatment | |
| NZ550174A (en) | Combinations comprising a vasculostatic compound such as vatalanib and epothilones, and pharmaceutical uses thereof | |
| JP5340393B2 (ja) | 腎細胞癌の治療のための３，３’，４，４’−テトラヒドロキシ−２，２’−ビピリジン−ｎ，ｎ’−ジオキシド | |
| JP2006507319A5 (enExample) | ||
| Yao et al. | 78 POSTER Combined anti-VEGFR and anti-PDGFR actions of sunitinib on blood vessels in preclinical tumor models | |
| RU2008127264A (ru) | Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза | |
| TW202327579A (zh) | Ｔｅａｄ抑制劑的給藥方案 | |
| NZ509529A (en) | A pharmaceutical preparation containing platinum complex compounds and the use thereof for treating tumoral diseases | |
| US20070021432A1 (en) | Treatment of mesothelioma | |
| JP2006503874A5 (enExample) | ||
| JP2006512360A (ja) | ＶｏｎＨｉｐｐｅｌ−Ｌｉｎｄａｕ病の処置 | |
| JP2006502195A5 (enExample) | ||
| WO2002092096A1 (en) | Antitumor agents | |
| JP2005515164A5 (enExample) | ||
| JP2002518467A5 (enExample) | ||
| Verschraegen et al. | 714 POSTER Phase I tolerability/safety of sunitinib in combination with capecitabine in patients (pts) with advanced solid tumors | |
| Rudolph et al. | 712 POSTER In vivo efficacy of BI 2536, a potent and selective inhibitor of the mitotic kinase Plk1, in human hematopoietic cancers | |
| WO2004002485A1 (en) | Combination comprising a vasculostatic compound and an alkylating agent for the treatmemt of a tumor | |
| Giannios et al. | 713 POSTER Molecularly targeted immunochemotherapeutic formulation (SEVINA) composed of pegylated trispecific disulfide linked Fv (sdFv) targeting epitopes of EGFR, PTHrP and RANKL conjugated covalently with SATA to vinorelbine eradicated osteolytic metastases of multiple myeloma inhibiting proliferation of tumor associated and bone microvascular endothelial cells inducing ADCC, AMP and type I, II, III PCD | |
| WO2013064567A1 (en) | 2-carboxamide cycloamino urea derivatives for use in treating vegf - dependent diseases |